BioCentury | Oct 12, 2020
Finance
Priothera raises €30 million to develop onetime Novartis candidate in AML transplantation setting
...modulator for acute myelogenous leukemia patients undergoing hematopoietic stem cell transplantation.The group believes mocravimod, which Priothera Ltd....
